

Supplementary Documents [IFRS]

Financial results for the fiscal year 2024 (FY2024)

Astellas Pharma Inc.

- FY2024 Financial Results
 - For the year ended March 31, 2025
 - Three months ended March 31, 2025
- Pipeline list

Cautionary Notes

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

[For the year ended March 31, 2025]

1. Consolidated Results (Full Basis)

	Unit: B¥				Change from Forecasts FY24	
	FY23 Full Year	FY24 Full Year	Change	Change (%)	FY25 Full Year	Change (%)
Revenue	1,603.7	1,912.3	308.7	19.2%	1,930.0	0.9%
Cost of sales	292.5	349.2	56.7	19.4%	373.0	6.8%
Gross profit	1,311.2	1,563.1	251.9	19.2%	1,557.0	-0.4%
SG&A expenses	740.1	843.0	102.9	13.9%	805.0	-4.5%
XTANDI co-promotion fee in the United States	194.9	252.6	57.7	29.6%	229.0	-9.3%
SG&A excl. the above	545.2	590.5	45.2	8.3%	576.0	-2.5%
Ratio to Revenue	34.0%	30.9%			29.8%	
R&D expenses	294.2	327.7	33.5	11.4%	342.0	4.4%
Ratio to Revenue	18.3%	17.1%			17.7%	
Amortisation of intangible assets	98.8	136.8	37.9	38.4%		
Gain on divestiture of intangible assets	9.7	1.0	-8.7	-89.2%		
Share of profit (loss) of investments accounted for using equity method	-3.2	-0.3	2.9	-		
Other income	8.7	20.3	11.7	134.1%		
Fair value remeasurements on contingent consideration	2.6	16.7	14.0	532.4%		
Other expenses	167.8	235.8	68.0	40.5%		
Impairment losses for property, plant and equipment	15.1	0.0	-15.1	-99.7%		
Impairment losses for intangible assets	63.8	187.6	123.8	194.0%		
Restructuring costs	25.4	15.5	-9.9	-38.9%		
Net foreign exchange losses	0.8	18.6	17.8	-		
Fair value remeasurements on contingent consideration	24.7	-	-24.7	-		
Replacement awards with business combination*	33.4	-	-33.4	-		
Operating profit	25.5	41.0	15.5	60.8%	160.0	289.9%
Ratio to Revenue	1.6%	2.1%			8.3%	
Finance income	11.5	7.9	-3.6	-31.3%		
Finance expenses	12.0	17.7	5.7	47.3%		
Profit before tax	25.0	31.2	6.3	25.1%	150.0	380.2%
Income tax expense	7.9	-19.5	-27.4	-		
Profit	17.0	50.7	33.7	197.7%	130.0	156.2%
Comprehensive income	205.6	48.9	-156.7	-76.2%		

(*) Payment for Iveric Bio's unvested share-based payments, such as share options

2. Consolidated Results (Core Basis)

		Unit: B¥			Forecasts	Change from FY24
	FY23 Full Year	FY24 Full Year	Change	Change (%)	FY25 Full Year	Change (%)
Revenue	1,603.7	1,912.3	308.7	19.2%	1,930.0	0.9%
Cost of sales	292.5	349.2	56.7	19.4%	373.0	6.8%
Gross profit	1,311.2	1,563.1	251.9	19.2%	1,557.0	-0.4%
SG&A expenses	740.1	843.0	102.9	13.9%	805.0	-4.5%
XTANDI co-promotion fee in the United States	194.9	252.6	57.7	29.6%	229.0	-9.3%
SG&A excl. the above	545.2	590.5	45.2	8.3%	576.0	-2.5%
Ratio to Revenue	34.0%	30.9%			29.8%	
R&D expenses	294.2	327.7	33.5	11.4%	342.0	4.4%
Ratio to Revenue	18.3%	17.1%			17.7%	
Operating profit	276.9	392.4	115.5	41.7%	410.0	4.5%
Ratio to Revenue	17.3%	20.5%			21.2%	
Finance income	11.5	7.9	-3.6	-31.3%		
Finance expenses	12.0	17.7	5.7	47.3%		
Profit before tax	276.3	382.6	106.3	38.5%		
Income tax expense	53.1	87.0	33.8	63.6%		
Profit	223.2	295.7	72.5	32.5%	304.0	2.8%

3. Exchange Rate

		Unit: yen			Forecasts
	FY23 Ave.	FY24 Ave.	FY23 End	FY24 End	FY25 Full Year
USD/Yen	145	152	151	150	140
EUR/Yen	157	164	163	162	160

* Fx impacts: Revenue +68.1 billion yen and Core operating profit +15.1 billion yen

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY23 Full year			FY24 Full year		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Revenue	1,603.7	-	1,603.7	1,912.3	-	1,912.3
Cost of sales	292.5	-	292.5	349.2	-	349.2
Gross profit	1,311.2	-	1,311.2	1,563.1	-	1,563.1
SG&A expenses	740.1	-	740.1	843.0	-	843.0
R&D expenses	294.2	-	294.2	327.7	-	327.7
Amortisation of intangible assets *	98.8	-98.8	-	136.8	-136.8	-
Gain on divestiture of intangible assets *	9.7	-9.7	-	1.0	-1.0	-
Share of profit (loss) of investments accounted for using equity method *	-3.2	3.2	-	-0.3	0.3	-
Other income *	8.7	-8.7	-	20.3	-20.3	-
Other expenses *	167.8	-167.8	-	235.8	-235.8	-
Operating profit	25.5	251.4	276.9	41.0	351.4	392.4
Finance income	11.5	-	11.5	7.9	-	7.9
Finance expenses	12.0	-	12.0	17.7	-	17.7
Profit before tax	25.0	251.4	276.3	31.2	351.4	382.6
Income tax expense	7.9	45.2	53.1	-19.5	106.5	87.0
Profit	17.0	206.2	223.2	50.7	244.9	295.7

* The definition of core-basis was changed from Q1/FY2024. In addition to the old definition's adjustments, 'Amortisation of intangible assets', 'Gain on divestiture of intangible assets' and 'Share of profit (loss) of investments accounted for using equity method' were newly excluded as new adjustment items. All figures above reflect this change.

"Other income" and "Other expenses" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

5. Revenue by Region

		Unit: B¥				Change from Forecasts FY24	
		FY23 Full Year	FY24 Full Year	Change	Change (%)	FY25 Full Year	Change (%)
Revenue		1,603.7	1,912.3	308.7	19.2%	1,930.0	0.9%
	Japan	270.1	267.0	-3.1	-1.2%	285.0	6.7%
	Ratio to Revenue	16.8%	14.0%			14.8%	
	United States	663.1	866.4	203.3	30.7%	856.0	-1.2%
	Ratio to Revenue	41.3%	45.3%			44.4%	
	Established Markets	415.6	485.4	69.8	16.8%	492.0	1.4%
	Ratio to Revenue	25.9%	25.4%			25.5%	
	China	70.6	78.3	7.7	10.9%	89.0	13.7%
	Ratio to Revenue	4.4%	4.1%			4.6%	
	International Markets	177.0	203.5	26.5	15.0%	202.0	-0.7%
	Ratio to Revenue	11.0%	10.6%			10.5%	

- Established Markets: Europe, Canada, etc.

- China: China, Hong Kong

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

- From Q1/FY2024, the commercial segment of Taiwan was changed from China to International Markets. All figures above reflect this change.

6. Per Share Information

	FY23 Full Year	FY24 Full Year	Forecasts FY25 Full Year
The number of shares issued (thousand)	1,809,663	1,809,663	
Treasury Shares (thousand)	16,561	19,353	
The number of shares issued after deducting Treasury Shares (thousand)	1,793,101	1,790,309	
Earnings per share (yen)	9.51	28.35	72.61
Earnings per share (yen) core basis	124.46	165.17	169.80
Dividend per share (yen)	70	74	78
Return on Equity (%)	1.1%	3.3%	
Dividend on Equity (%)	8.1%	8.5%	

- The numbers of shares stated in the business report are presented by disregarding any number of shares less than the specified units.

7. Investment in Property, Plant and Equipment

Depreciation/Amortisation

		Unit: B¥				Change from Forecasts FY24	
		FY23 Full Year	FY24 Full Year	Change	Change (%)	FY25 Full Year	Change (%)
Investment in Property, Plant and Equipment		35.4	47.8	12.4	34.9%	55.0	15.1%
Depreciation (PP&E)		42.4	44.9	2.5	5.9%	45.0	0.2%
Amortisation of Intangible Assets (incl. software, etc.)		115.4	154.2	38.8	33.6%	155.0	0.5%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

8. Sales of major products

1) Global

Unit: B¥

		FY23 Full Year	FY24 Full Year	Change	Change (%)
XTANDI		750.5	912.3	161.8	21.6%
	Japan	56.7	57.9	1.2	2.1%
	United States	379.7	491.7	112.0	29.5%
	Established Markets	231.6	262.1	30.5	13.2%
	China	12.2	16.3	4.1	33.9%
	International Markets	70.3	84.3	14.0	20.0%
PADCEV		85.4	164.1	78.7	92.2%
	Japan	8.5	12.6	4.1	47.9%
	United States	60.7	109.1	48.5	79.9%
	Established Markets	14.7	32.7	18.0	122.0%
	China	0.1	3.9	3.8	-
	International Markets	1.3	5.7	4.4	328.8%
IZERVAY		12.1	58.3	46.2	380.6%
	United States	12.1	58.3	46.1	380.5%
VEOZAH		7.3	33.8	26.5	363.6%
	United States	7.2	30.8	23.6	330.3%
	Established Markets	0.1	2.7	2.6	-
	International Markets	0.0	0.3	0.3	-
VYLOY		-	12.2	12.2	-
	Japan	-	5.2	5.2	-
	United States	-	4.9	4.9	-
	Established Markets	-	2.2	2.2	-
	China	-	-	-	-
	International Markets	-	-	-	-
XOSPATA		55.1	68.0	12.9	23.4%
	Japan	4.4	4.7	0.3	7.7%
	United States	28.6	35.0	6.5	22.7%
	Established Markets	15.2	18.9	3.7	24.3%
	China	3.1	3.9	0.7	24.0%
	International Markets	3.9	5.5	1.6	41.8%
BETANIS/MYRBETRIQ/BETMIGA		198.1	170.0	-28.0	-14.2%
PROGRAF		203.1	201.0	-2.1	-1.0%

Change from
FY24

Forecasts		FY25 Full Year	Change (%)
		868.0	-4.9%
	Japan	60.0	3.6%
	United States	446.0	-9.3%
	Established Markets	261.0	-0.4%
	China	18.0	10.4%
	International Markets	82.0	-2.7%
		200.0	21.9%
	Japan	27.0	114.3%
	United States	111.0	1.7%
	Established Markets	40.0	22.3%
	China	12.0	207.7%
	International Markets	9.0	57.9%
		105.0	80.1%
	United States	105.0	80.1%
		50.0	47.9%
	United States	39.0	26.6%
	Established Markets	8.0	196.3%
	International Markets	1.0	233.3%
		40.0	227.9%
	Japan	14.0	169.2%
	United States	16.0	226.5%
	Established Markets	5.0	127.3%
	China	4.0	-
	International Markets	1.0	-
		75.0	10.3%
	Japan	6.0	27.7%
	United States	36.0	2.9%
	Established Markets	19.0	0.5%
	China	5.0	28.2%
	International Markets	7.0	27.3%
		134.0	-21.2%
		186.0	-7.5%

- Established Markets: Europe, Canada, etc.

- China: China, Hong Kong

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

- From Q1/FY2024, the commercial segment of Taiwan was changed from China to International Markets. All figures above reflect this change.

- PADCEV (United States): Co-promotion revenue from Pfizer

- VEOZAH: Approved as "VEOZA" in ex-US

2) Revenue by region

(1) Japan

		Unit: B¥				Change from FY24	
		FY23 Full Year	FY24 Full Year	Change	Change (%)	Forecasts FY25 Full Year	Change (%)
Revenue		270.1	267.0	-3.1	-1.2%	285.0	6.7%
	XTANDI	56.7	57.9	1.2	2.1%	60.0	3.6%
	PADCEV	8.5	12.6	4.1	47.9%	27.0	114.3%
	VYLOY	-	5.2	5.2	-	14.0	169.2%
	XOSPATA	4.4	4.7	0.3	7.7%	6.0	27.7%
	EVRENZO	2.1	1.6	-0.5	-22.4%		
	BETANIS	27.4	24.6	-2.7	-10.0%	24.0	-2.4%
	PROGRAF (Including GRACEPTOR)	29.5	21.2	-8.3	-28.0%	18.0	-15.1%
	SUGLAT [Family]	27.9	26.4	-1.5	-5.3%	24.0	-9.1%
	SUJANU	11.0	10.5	-0.5	-5.0%		
	BLINCYTO	11.2	13.4	2.2	19.4%		
	EVENITY	48.8	57.9	9.1	18.5%		
	CIMZIA	10.0	9.4	-0.6	-6.0%		

(2) United States

		Unit: M\$				Change from FY24	
		FY23 Full Year	FY24 Full Year	Change	Change (%)	Forecasts FY25 Full Year	Change (%)
Revenue		4,587	5,683	1,096	23.9%	6,120	7.5%
	XTANDI	2,627	3,225	599	22.8%	3,180	-1.4%
	PADCEV	420	716	296	70.6%	790	10.3%
	IZERVAY	84	382	298	355.6%	750	96.3%
	VEOZAH	50	202	153	308.0%	280	38.6%
	VYLOY	-	32	32	-	120	275.0%
	XOSPATA	198	230	32	16.3%	260	13.0%
	MYRBETRIQ	701	410	-291	-41.6%	210	-48.8%
	PROGRAF	69	68	-2	-2.3%		
	CRESEMBA	259	310	51	19.5%	350	12.9%

(3) Established Markets

		Unit: M€				Change from FY24	
		FY23 Full Year	FY24 Full Year	Change	Change (%)	Forecasts FY25 Full Year	Change (%)
Revenue		2,651	2,967	316	11.9%	3,070	3.8%
	XTANDI	1,477	1,602	124	8.4%	1,630	1.7%
	PADCEV	94	200	106	112.7%	250	25.0%
	VEOZA	1	17	16	-	50	194.1%
	VYLOY	-	13	13	-	30	130.8%
	XOSPATA	97	115	18	19.1%	120	4.3%
	EVRENZO	13	19	7	53.7%		
	BETMIGA	327	382	55	16.9%	390	2.1%
	PROGRAF	471	459	-13	-2.7%	440	-4.1%

- Established Markets: Europe, Canada, etc.

(4) China

		Unit: B¥				Change from Forecasts FY24	
		FY23 Full Year	FY24 Full Year	Change	Change (%)	FY25 Full Year	Change (%)
Revenue		70.6	78.3	7.7	10.9%	89.0	13.7%
	XTANDI	12.2	16.3	4.1	33.9%	18.0	10.4%
	PADCEV	0.1	3.9	3.8	-	12.0	207.7%
	XOSPATA	3.1	3.9	0.7	24.0%	5.0	28.2%
	BETMIGA	1.6	1.6	0.0	2.5%		
	PROGRAF	43.5	43.0	-0.4	-1.0%	40.0	-7.0%

- China: China, Hong Kong

- From Q1/FY2024, the commercial segment of Taiwan was changed from China to International Markets. All figures above reflect this change.

(5) International Markets

		Unit: B¥				Change from Forecasts FY24	
		FY23 Full Year	FY24 Full Year	Change	Change (%)	FY25 Full Year	Change (%)
Revenue		177.0	203.5	26.5	15.0%	202.0	-0.7%
	XTANDI	70.3	84.3	14.0	20.0%	82.0	-2.7%
	PADCEV	1.3	5.7	4.4	328.8%	9.0	57.9%
	VEOZA	0.0	0.3	0.3	-	1.0	233.3%
	XOSPATA	3.9	5.5	1.6	41.8%	7.0	27.3%
	BETMIGA	16.6	18.8	2.2	13.5%	17.0	-9.6%
	PROGRAF	46.3	51.4	5.1	11.1%	48.0	-6.6%
	HARNAL	20.8	21.6	0.8	4.0%		

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

- From Q1/FY2024, the commercial segment of Taiwan was changed from China to International Markets. All figures above reflect this change.

9. Consolidated statements of financial position

Unit: B¥

	FY23 End	FY24 End	Change
Assets	3,569.6	3,339.5	-230.1
Non-current assets	2,374.9	2,138.2	-236.7
Property, plant and equipment	293.7	328.9	35.2
Goodwill	418.7	415.2	-3.5
Intangible assets	1,453.8	1,123.7	-330.1
Trade and other receivables	20.0	18.5	-1.6
Investments accounted for using equity method	15.7	19.0	3.3
Deferred tax assets	45.6	98.1	52.5
Other financial assets	108.7	106.2	-2.5
Other non-current assets	18.6	28.6	10.0
Current assets	1,194.7	1,201.3	6.6
Inventories	248.7	297.3	48.5
Trade and other receivables	535.0	632.5	97.5
Income tax receivable	13.1	13.7	0.6
Other financial assets	28.8	29.9	1.2
Other current assets	32.2	39.2	7.0
Cash and cash equivalents	335.7	188.4	-147.3
Assets held for sale	1.2	0.4	-0.9

Unit: B¥

	FY23 End	FY24 End	Change
Equity and Liabilities	3,569.6	3,339.5	-230.1
Equity	1,596.0	1,513.3	-82.7
Equity attributable to owners of the parent	1,596.0	1,513.3	-82.7
Share capital	103.0	103.0	-
Capital surplus	184.1	185.3	1.2
Treasury shares	-33.8	-37.5	-3.7
Retained earnings	809.4	740.9	-68.5
Other components of equity	533.3	521.6	-11.7
Liabilities	1,973.6	1,826.3	-147.3
Non-current liabilities	687.9	764.7	76.8
Bonds and borrowings	447.7	564.9	117.2
Trade and other payables	2.2	-	-2.2
Income tax payable	-	3.2	3.2
Deferred tax liabilities	51.3	5.4	-46.0
Retirement benefit liabilities	24.7	22.7	-1.9
Provisions	7.4	8.1	0.8
Other financial liabilities	105.6	106.8	1.2
Other non-current liabilities	49.0	53.6	4.6
Current liabilities	1,285.7	1,061.6	-224.1
Bonds and borrowings	472.3	266.5	-205.7
Trade and other payables	185.2	187.8	2.6
Income tax payable	38.5	34.5	-4.0
Provisions	15.7	17.3	1.6
Other financial liabilities	97.6	20.1	-77.4
Other current liabilities	476.5	535.3	58.8

10. Employees

Number of employees

	FY23 End	FY24 End
Total	14,754	13,643

11. Shareholders

	FY23 End	FY24 End
Banks	36.3%	36.3%
Securities	6.6%	7.3%
Other companies	3.4%	2.5%
Foreign companies	39.9%	38.6%
Individuals and others	13.7%	15.3%
Treasury Stock*	0.0%	0.0%

* Treasury Stock does not include shares owned by the executive compensation BIP (Board Incentive Plan) trust and ESOP (Employee Stock Ownership Plan) trust.

[Three months ended March 31, 2025]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY24							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue	473.1	26.2%	462.5	17.9%	517.4	22.6%	459.3	10.8%
Cost of sales	91.1	32.2%	82.7	11.1%	98.5	29.8%	76.9	5.0%
Gross profit	382.0	24.8%	379.8	19.5%	418.9	21.1%	382.4	12.0%
SG&A expenses	206.9	23.0%	199.5	11.3%	225.3	12.9%	211.3	9.4%
XTANDI co-promotion fee in the United States	61.6	38.2%	64.4	32.9%	74.1	39.2%	52.5	7.9%
SG&A excl. the above	145.3	17.5%	135.1	3.3%	151.2	3.4%	158.9	9.9%
Ratio to Revenue	30.7%		29.2%		29.2%		34.6%	
R&D expenses	86.8	34.4%	85.5	10.5%	79.1	6.3%	76.2	-2.1%
Ratio to Revenue	18.4%		18.5%		15.3%		16.6%	
Amortisation of intangible assets	35.0	285.9%	34.2	38.8%	35.0	7.8%	32.6	-0.3%
Gain on divestiture of intangible assets	0.9	-	-	-	0.1	-73.8%	0.1	-
Share of profit (loss) of investments accounted for using equity method	1.9	181.2%	-0.5	-	-2.1	-	0.4	-
Other income	4.9	25.2%	-0.4	-	-0.1	-	15.9	-
Fair value remeasurements on contingent consideration	2.0	-22.6%	0.6	690.9%	-0.4	-	14.4	-
Other expenses	10.4	-55.0%	16.6	-57.3%	193.7	727.2%	15.2	-81.9%
Impairment losses for intangible assets	0.6	-80.4%	0.0	-98.5%	180.5	-	6.5	-88.9%
Restructuring costs	2.6	89.9%	5.3	268.3%	2.5	-84.2%	5.2	-25.9%
Net foreign exchange losses	-	-	12.2	-	3.9	-	2.5	186.2%
Fair value remeasurements on contingent consideration	5.7	-43.7%	-5.1	-	3.3	-42.9%	-4.0	-
Operating profit	50.7	10.6%	43.1	359.8%	-116.2	-	63.5	-
Ratio to Revenue	10.7%		9.3%		-22.5%		13.8%	
Finance income	4.3	14.7%	0.5	-77.2%	2.1	74.5%	0.9	-77.2%
Finance expenses	4.5	65.2%	5.0	122.5%	4.2	49.4%	3.9	-6.7%
Profit before tax	50.5	7.8%	38.5	307.1%	-118.4	-	60.6	-
Income tax expense	12.9	-6.0%	2.6	-61.1%	-20.7	-	-14.3	-
Profit	37.6	13.5%	35.9	-	-97.7	-	74.9	-
Comprehensive income	149.5	11.1%	-148.1	-	29.2	-	18.3	-80.0%

2. Consolidated Results (Core Basis)

Unit: B¥

		FY24							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		473.1	26.2%	462.5	17.9%	517.4	22.6%	459.3	10.8%
Cost of sales		91.1	32.2%	82.7	11.1%	98.5	29.8%	76.9	5.0%
Gross profit		382.0	24.8%	379.8	19.5%	418.9	21.1%	382.4	12.0%
SG&A expenses		206.9	23.0%	199.5	11.3%	225.3	12.9%	211.3	9.4%
XTANDI co-promotion fee in the United States		61.6	38.2%	64.4	32.9%	74.1	39.2%	52.5	7.9%
SG&A excl. the above		145.3	17.5%	135.1	3.3%	151.2	3.4%	158.9	9.9%
	Ratio to Revenue	30.7%		29.2%		29.2%		34.6%	
R&D expenses		86.8	34.4%	85.5	10.5%	79.1	6.3%	76.2	-2.1%
	Ratio to Revenue	18.4%		18.5%		15.3%		16.6%	
Operating profit		88.3	20.5%	94.8	55.1%	114.5	58.7%	94.9	34.8%
	Ratio to Revenue	18.7%		20.5%		22.1%		20.7%	
Finance income		4.3	14.7%	0.5	-77.2%	2.1	74.5%	0.9	-77.2%
Finance expenses		4.5	65.2%	5.0	122.5%	4.2	49.4%	3.9	-6.7%
Profit before tax		88.1	18.6%	90.3	47.5%	112.3	59.3%	91.9	30.7%
Income tax expense		21.0	27.8%	16.7	69.1%	30.0	104.5%	19.3	58.1%
Profit		67.2	15.9%	73.6	43.3%	82.3	47.4%	72.6	25.0%

3. Revenue by Region

Unit: B¥

		FY24							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		473.1	26.2%	462.5	17.9%	517.4	22.6%	459.3	10.8%
	Japan	66.7	-2.4%	66.9	-3.5%	72.2	-1.7%	61.3	3.7%
	Ratio to Revenue	14.1%		14.5%		14.0%		13.3%	
	United States	212.1	41.4%	207.2	32.2%	245.8	40.7%	201.3	10.8%
	Ratio to Revenue	44.8%		44.8%		47.5%		43.8%	
	Established Markets	121.0	25.0%	119.0	16.3%	123.8	15.5%	121.6	11.4%
	Ratio to Revenue	25.6%		25.7%		23.9%		26.5%	
	China	18.7	2.4%	19.0	4.8%	20.4	14.5%	20.3	23.1%
	Ratio to Revenue	3.9%		4.1%		3.9%		4.4%	
	International Markets	52.0	33.2%	48.0	8.8%	52.2	7.0%	51.3	14.0%
	Ratio to Revenue	11.0%		10.4%		10.1%		11.2%	

- Established Markets: Europe, Canada, etc.

- China: China, Hong Kong

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

- From Q1/FY2024, the commercial segment of Taiwan was changed from China to International Markets. All figures above reflect this change.

4. Investment in Property, Plant and Equipment

Depreciation/Amortisation

Unit: B¥

		FY24							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Investment in Property, Plant and Equipment		13.5	44.8%	15.2	104.5%	12.8	109.5%	6.3	-49.8%
Depreciation (PP&E)		10.9	6.9%	11.4	12.1%	11.7	12.1%	11.0	-5.9%
Amortisation of Intangible Assets (incl. software, etc.)		39.4	201.7%	38.6	34.1%	39.5	8.0%	36.7	-0.7%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

5. Sales of major products

1) Global

Unit: B¥

		FY24							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
XTANDI		224.2	28.8%	227.4	21.7%	251.4	26.3%	209.2	9.8%
	Japan	14.9	2.9%	13.9	-3.4%	15.5	1.8%	13.6	8.0%
	United States	119.8	38.0%	125.4	32.7%	144.1	39.1%	102.3	8.0%
	Established Markets	65.7	20.3%	66.0	14.8%	66.4	12.0%	64.0	6.3%
	China	3.0	-9.2%	3.9	-15.8%	4.2	101.6%	5.2	141.4%
	International Markets	20.9	40.3%	18.3	14.9%	21.1	12.8%	24.0	15.7%
PADCEV		38.4	152.3%	37.0	111.6%	41.6	81.5%	47.1	58.3%
	Japan	2.5	13.1%	2.4	13.2%	3.7	73.0%	3.9	96.9%
	United States	27.2	158.9%	26.0	108.3%	27.3	70.8%	28.7	32.2%
	Established Markets	7.5	211.9%	7.5	175.0%	8.6	103.2%	9.1	69.7%
	China	0.1	-	0.1	-	0.1	293.5%	3.6	-
	International Markets	1.1	-	1.0	521.5%	1.7	286.6%	1.8	187.9%
IZERVAY		12.7	-	15.4	-	16.3	298.6%	13.8	101.9%
	United States	12.7	-	15.4	-	16.3	298.6%	13.8	101.8%
VEOZAH		6.6	972.0%	8.2	-	9.6	320.8%	9.4	151.2%
	United States	6.1	895.9%	7.4	-	8.7	278.2%	8.5	137.7%
	Established Markets	0.4	-	0.7	-	0.9	-	0.7	457.1%
	International Markets	0.0	-	0.1	-	0.1	-	0.2	830.5%
VYLOY		0.3	-	0.9	-	3.7	-	7.3	-
	Japan	0.3	-	0.9	-	1.9	-	2.1	-
	United States	-	-	-	-	1.1	-	3.7	-
	Established Markets	-	-	0.0	-	0.7	-	1.5	-
XOSPATA		17.3	32.8%	17.5	31.8%	18.3	21.8%	14.9	8.1%
	Japan	1.3	5.8%	1.1	6.9%	1.3	9.4%	1.0	9.1%
	United States	8.9	25.9%	8.9	28.4%	9.5	34.2%	7.7	3.3%
	Established Markets	4.6	39.5%	4.5	15.7%	4.6	15.9%	5.1	28.5%
	China	1.4	162.0%	1.6	148.7%	1.5	-7.6%	-0.7	-
	International Markets	1.1	23.8%	1.4	77.1%	1.3	19.8%	1.7	52.5%
BETANIS/MYRBETRIQ/BETMIGA		46.1	-6.4%	31.5	-32.5%	47.0	-0.1%	45.5	-17.5%
PROGRAF		53.9	9.8%	50.1	-1.8%	51.7	-6.6%	45.4	-4.9%

- Established Markets: Europe, Canada, etc.

- China: China, Hong Kong

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

- From Q1/FY2024, the commercial segment of Taiwan was changed from China to International Markets. All figures above reflect this change.

- PADCEV (United States): Co-promotion revenue from Pfizer

- VEOZAH: Approved as "VEOZA" in ex-US

2) Revenue by region

(1) Japan

Unit: B¥

		FY24							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		66.7	-2.4%	66.9	-3.5%	72.2	-1.7%	61.3	3.7%
	XTANDI	14.9	2.9%	13.9	-3.4%	15.5	1.8%	13.6	8.0%
	PADCEV	2.5	13.1%	2.4	13.2%	3.7	73.0%	3.9	96.9%
	VYLOY	0.3	-	0.9	-	1.9	-	2.1	-
	XOSPATA	1.3	5.8%	1.1	6.9%	1.3	9.4%	1.0	9.1%
	EVRENZO	0.5	-16.3%	0.4	-22.2%	0.4	-25.8%	0.3	-26.5%
	BETANIS	6.6	-9.6%	5.9	-13.7%	6.7	-7.4%	5.4	-9.5%
	PROGRAF (Including GRACEPTOR)	6.4	-20.7%	5.7	-22.5%	5.2	-37.0%	4.1	-32.4%
	SUGLAT [Family]	7.0	-4.8%	6.5	-7.9%	7.2	-4.4%	5.7	-3.9%
	SUJANU	2.8	-4.6%	2.6	-4.9%	2.9	-6.2%	2.3	-4.0%
	BLINCYTO	3.2	34.1%	3.3	25.8%	4.0	21.7%	2.9	-1.0%
	EVENITY	13.8	19.6%	13.7	14.3%	15.5	17.2%	14.9	23.3%
	CIMZIA	2.5	-2.5%	2.4	-10.1%	2.5	-3.7%	2.0	-7.9%

(2) United States

Unit: M\$

		FY24							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		1,360	24.6%	1,390	28.2%	1,612	36.0%	1,321	7.7%
	XTANDI	768	21.6%	840	28.5%	945	34.4%	672	5.4%
	PADCEV	174	128.1%	174	101.5%	179	64.1%	188	27.5%
	IZERVAY	82	-	103	-	107	276.1%	91	92.8%
	VEOZAH	39	777.6%	50	998.0%	57	258.4%	56	127.6%
	VYLOY	-	-	-	-	8	-	24	-
	XOSPATA	57	10.9%	59	24.8%	62	30.2%	51	0.7%
	MYRBETRIQ	120	-36.7%	40	-74.6%	124	-14.5%	126	-40.1%
	PROGRAF	17	1.0%	17	-4.6%	17	-7.7%	16	3.2%
	CRESEMBA	70	12.4%	77	23.7%	84	20.7%	79	21.0%

(3) Established Markets

Unit: M€

		FY24							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		721	11.4%	727	11.7%	761	12.8%	758	11.8%
	XTANDI	391	7.2%	403	10.2%	408	9.4%	399	6.8%
	PADCEV	45	178.0%	46	163.7%	53	96.6%	57	68.1%
	VEOZA	3	-	4	-	5	-	4	444.0%
	VYLOY	-	-	0	-	4	-	9	-
	XOSPATA	27	24.3%	28	10.9%	28	13.1%	32	28.7%
	EVRENZO	5	119.2%	5	87.3%	5	32.3%	5	15.7%
	BETMIGA	92	19.5%	91	11.5%	99	19.3%	101	17.4%
	PROGRAF	115	-3.7%	112	-3.0%	116	-3.9%	116	0.0%

- Established Markets: Europe, Canada, etc.

(4) China

Unit: B¥

		FY24							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		18.7	2.4%	19.0	4.8%	20.4	14.5%	20.3	23.1%
	XTANDI	3.0	-9.2%	3.9	-15.8%	4.2	101.6%	5.2	141.4%
	PADCEV	0.1	-	0.1	-	0.1	293.5%	3.6	-
	XOSPATA	1.4	162.0%	1.6	148.7%	1.5	-7.6%	-0.7	-
	BETMIGA	0.4	8.2%	0.4	31.6%	0.4	1.7%	0.3	-23.2%
	PROGRAF	11.2	-2.3%	10.7	4.2%	11.5	5.5%	9.7	-11.1%

- China: China, Hong Kong

- From Q1/FY2024, the commercial segment of Taiwan was changed from China to International Markets. All figures above reflect this change.

(5) International Markets

Unit: B¥

		FY24							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		52.0	33.2%	48.0	8.8%	52.2	7.0%	51.3	14.0%
	XTANDI	20.9	40.3%	18.3	14.9%	21.1	12.8%	24.0	15.7%
	PADCEV	1.1	-	1.0	521.5%	1.7	286.6%	1.8	187.9%
	VEOZA	0.0	-	0.1	-	0.1	-	0.2	830.5%
	XOSPATA	1.1	23.8%	1.4	77.1%	1.3	19.8%	1.7	52.5%
	BETMIGA	4.9	24.5%	4.7	15.9%	4.8	4.5%	4.5	10.6%
	PROGRAF	14.4	52.8%	13.0	1.6%	13.6	-5.5%	10.5	8.0%
	HARNAL	5.3	9.1%	5.6	6.2%	5.8	12.1%	4.8	-10.7%

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

- From Q1/FY2024, the commercial segment of Taiwan was changed from China to International Markets. All figures above reflect this change.

R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China.

As of Apr 2025

Underlined items indicate changes from the previous announcement in Feb 2025.

Strategic Brands (1/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
enfortumab vedotin ASG-22ME (PADCEV)	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Muscle-invasive bladder cancer (combo with pembrolizumab)	P-III	In-house [Co-development with Pfizer]	
			Other solid tumors	P-II		
			Non-muscle-invasive bladder cancer	P-I		
gilteritinib ASP2215 (XOSPATA)	Small molecule	FLT3 inhibitor	Post-chemotherapy maintenance acute myeloid leukemia	P-III	In-house	
			Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
			Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III		
			Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-II		
			Acute myeloid leukemia in pediatric patients	P-III		

Strategic Brands (2/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensors **	Remarks
zolbetuximab IMAB362 (VYLOY)	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma (combo with pembrolizumab and chemotherapy)	P-III	In-house (Ganymed)	
			Pancreatic adenocarcinoma	P-II		
fezolinetant ESN364 (VEOZAH***)	Small molecule	NK3 receptor antagonist	Vasomotor symptoms due to menopause	China P-III Japan P-III	In-house (Ogeda)	
			Vasomotor symptoms in breast cancer patients on adjuvant endocrine therapy	P-III		
avacincaptad pegol (IZERVAY)	Pegylated RNA aptamer	Complement C5 inhibitor	<u>Geographic atrophy secondary to age-related macular degeneration</u>	Japan <u>Filed (Feb 2025)</u>		
			Stargardt disease	P-II	In-house (Iveric Bio)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

*** Approved as "VEOZA" in ex-US.

Updates from the previous announcement (Feb 2025):

enfortumab vedotin: Removed the description of the approval in China for locally advanced or metastatic urothelial cancer in Jan 2025.

zolbetuximab: Removed the description of the approval in China for locally advanced unresectable or metastatic HER2-negative, claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma in Dec 2024.

avacincaptad pegol: Submitted in Japan in Feb 2025 for geographic atrophy secondary to age-related macular degeneration.

Programs with Focus Area approach

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
Immuno-oncology	ASP1570	Small molecule	DGK ζ inhibitor	Cancer	P-I	In-house	
	ASP2138	Antibody	Anti-Claudin 18.2 and anti-CD3 bispecific antibody	Gastric and gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma	P-I	Xencor [Discovered through collaborative research]	
	ASP1002	Antibody	Anti-Claudin 4 and anti-CD137 bispecific antibody	Cancer	P-I	In-house	
	ASP1012	Oncolytic virus	Oncolytic virus encoding leptin-IL-2	Cancer	P-I	KaliVir	
Targeted Protein Degradation	ASP3082	Small molecule	KRAS G12D degrader	Cancer	P-I	In-house	
	ASP4396	Small molecule	KRAS G12D degrader	Cancer	P-I	In-house	
Genetic regulation	resamirigene bilparvovec AT132	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	
	zocaglusagene nuzaparvovec AT845	Gene therapy (AAV-based gene therapy)	GAA gene replacement to express GAA enzyme	Pompe disease	<u>P-II</u>	In-house (Audentes Therapeutics)	
Blindness and Regeneration	ASP7317	Cell therapy	Retinal pigment epithelial cells	Geographic atrophy secondary to age-related macular degeneration	P-I	In-house (Ocata Therapeutics)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Feb 2025):

AT845: Entered into Phase 2 for pompe disease.

Others

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
mirabegron YM178	Small molecule	β_3 receptor agonist	Neurogenic detrusor overactivity in pediatric patients (aged 6 months to less than 3 years)	Europe P-III	In-house	
roxadustat ASP1517/FG-4592	Small molecule	HIF-PH inhibitor	Anemia associated with chronic kidney disease in pediatric patients	Europe P-III	FibroGen	Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa.
abiraterone decanoate ASP5541 (PRL-02)	Small molecule	CYP17 lyase inhibitor	Prostate cancer	P-I	In-house (Propella Therapeutics)	
ASP5502	Small molecule	STING inhibitor	Primary Sjogren's syndrome	P-I	In-house	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Rx+ Program

As of Apr 2025

Category	Program	Concept	Status*	Partner	Remarks
Digital health	BlueStar	Digital therapeutic for the management of diabetes	Pivotal study (Japan)	Welldoc Roche Diabetes Care Japan	
	DIGITIVA	Non-invasive digital health solution for management of heart failure	Commercially available	Welldoc Eko	
Drug-device combination	pudexacianinium chloride ASP5354	Intraoperative ureter visualization for use in patients undergoing minimally invasive and open abdominopelvic surgeries	P-III	Stryker	
Implantable medical device	Implantable bladder device	Implantable device for underactive bladder	FDA approved to enter into early feasibility study	(iota Biosciences)	

* The list shows the most advanced stage if the stages are different depending on the region.